MAGUIRE; Martin P.

Patent Applications and Registrations

Patent applications and USPTO patent grants for MAGUIRE; Martin P..The latest application filed is for "highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof".

Company Profile

8.34.34

MAGUIRE; Martin P. - Plattsburgh NY
Maguire; Martin P. - Westmount CA
Maguire; Martin P. - Woburn MA
Maguire; Martin P. - Cambridge MA
Maguire, Martin P. - Mont Clare PA
Maguire; Martin P. - Louisville KY
Maguire; Martin P. - King of Prussia PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20220296556 - MAGUIRE; Martin P.	2022-09-22
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20220142963 - MAGUIRE; Martin P. ; et al.	2022-05-12
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20220040139 - MAGUIRE; Martin P.	2022-02-10
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20210315855 - MAGUIRE; Martin P. ; et al.	2021-10-14
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20210205258 - MAGUIRE; Martin P.	2021-07-08
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20210059972 - MAGUIRE; Martin P. ; et al.	2021-03-04
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20200368195 - MAGUIRE; Martin P.	2020-11-26
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20200230097 - MAGUIRE; Martin P. ; et al.	2020-07-23
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20200121631 - Maguire; Martin P.	2020-04-23
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20190380993 - MAGUIRE; Martin P. ; et al.	2019-12-19
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20190269643 - MAGUIRE; Martin P.	2019-09-05
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20190142781 - MAGUIRE; Martin P. ; et al.	2019-05-16
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20190022048 - MAGUIRE; Martin P.	2019-01-24
Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof Grant 10,117,848 - Maguire November 6, 2	2018-11-06
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20180280339 - MAGUIRE; Martin P. ; et al.	2018-10-04
Short acting phenylalkylamine calcium channel blockers and uses thereof Grant 10,010,523 - Maguire , et al. July 3, 2	2018-07-03
Short acting phenylalkylamine calcium channel blockers and uses thereof Grant 10,010,522 - Maguire , et al. July 3, 2	2018-07-03
Short acting phenylalkylamine calcium channel blockers and uses thereof Grant 10,010,524 - Maguire , et al. July 3, 2	2018-07-03
Highly Water-soluble Salts Of A Short Acting Phenylalkylamine Calcium Channel Blocker And Uses Thereof App 20180110752 - MAGUIRE; Martin P.	2018-04-26
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20170312241 - MAGUIRE; Martin P. ; et al.	2017-11-02
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20170312243 - MAGUIRE; Martin P. ; et al.	2017-11-02
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20170312242 - MAGUIRE; Martin P. ; et al.	2017-11-02
Short acting phenylalkylamine calcium channel blockers and uses thereof Grant 9,737,503 - Maguire , et al. August 22, 2	2017-08-22
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20160374982 - MAGUIRE; Martin P. ; et al.	2016-12-29
Short acting phenylalkylamine calcium channel blockers and uses thereof Grant 9,463,179 - Maguire , et al. October 11, 2	2016-10-11
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20160074354 - MAGUIRE; Martin P. ; et al.	2016-03-17
Short acting phenylalkylamine calcium channel blockers and uses thereof Grant 9,227,918 - Maguire , et al. January 5, 2	2016-01-05
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20140296335 - MAGUIRE; Martin P. ; et al.	2014-10-02
Short acting benzothiazepine calcium channel blockers and uses thereof Grant 8,501,727 - Maguire , et al. August 6, 2	2013-08-06
Short Acting Benzothiazepine Calcium Channel Blockers And Uses Thereof App 20110144087 - Maguire; Martin P. ; et al.	2011-06-16
Short Acting Phenylalkylamine Calcium Channel Blockers And Uses Thereof App 20100190852 - Maguire; Martin P. ; et al.	2010-07-29
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases Grant 7,550,597 - Myers , et al. June 23, 2	2009-06-23
Melanocortin-4 receptor binding compounds and methods of use thereof App 20080269217 - Vos; Tricia J. ; et al.	2008-10-30
Melanocortin-4 receptor binding compounds and methods of use thereof Grant 7,375,125 - Vos , et al. May 20, 2	2008-05-20
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases App 20050182054 - Myers, Michael R. ; et al.	2005-08-18
Antagonists of melanin concentrating hormone receptor Grant 6,921,821 - Blackburn , et al. July 26, 2	2005-07-26
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases Grant 6,852,712 - Myers , et al. February 8, 2	2005-02-08
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases Grant 6,846,815 - Myers , et al. January 25, 2	2005-01-25
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases Grant 6,821,962 - Myers , et al. November 23, 2	2004-11-23
Antagonists of melanin concentrating hormone receptor App 20040106645 - Blackburn, Christopher ; et al.	2004-06-03
Melanocortin-4 receptor binding compounds and methods of use thereof App 20040082779 - Vos, Tricia J. ; et al.	2004-04-29
Melanocortin-4 receptor binding compounds and methods of use thereof Grant 6,699,873 - Maguire , et al. March 2, 2	2004-03-02
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases Grant 6,696,434 - Myers , et al. February 24, 2	2004-02-24
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase App 20040014774 - Myers, Michael R. ; et al.	2004-01-22
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase Grant 6,645,969 - Myers , et al. November 11, 2	2003-11-11
Methods of treating insulin resistance syndrome and diabetes App 20030176390 - Herling, Andreas ; et al.	2003-09-18
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases App 20030144284 - Myers, Michael R. ; et al.	2003-07-31
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases App 20030139400 - Myers, Michael R. ; et al.	2003-07-24
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases App 20030139399 - Myers, Michael R. ; et al.	2003-07-24
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases App 20030130285 - Myers, Michael R. ; et al.	2003-07-10
Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties Grant 6,559,313 - Myers , et al. May 6, 2	2003-05-06
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases Grant 6,528,526 - Myers , et al. March 4, 2	2003-03-04
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases Grant 6,524,347 - Myers , et al. February 25, 2	2003-02-25
Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties App 20020099030 - Myers, Michael R. ; et al.	2002-07-25
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase Grant RE37,650 - Myers , et al. April 9, 2	2002-04-09
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases Grant 6,180,632 - Myers , et al. January 30, 2	2001-01-30
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinases Grant 6,159,978 - Myers , et al. December 12, 2	2000-12-12
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase Grant 6,057,320 - Spada , et al. May 2, 2	2000-05-02
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase Grant RE36,256 - Spada , et al. July 20, 1	1999-07-20
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase Grant 5,795,889 - Spada , et al. August 18, 1	1998-08-18
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties Grant 5,721,237 - Myers , et al. February 24, 1	1998-02-24
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase Grant 5,714,493 - Myers , et al. February 3, 1	1998-02-03
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase Grant 5,710,158 - Myers , et al. January 20, 1	1998-01-20
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase Grant 5,656,643 - Spada , et al. A	1997-08-12
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase Grant 5,646,153 - Spada , et al. July 8, 1	1997-07-08
Polyarylcarbamoylaza- and -carbamoylalkanedioic acids Grant 5,556,990 - Pauls , et al. September 17, 1	1996-09-17
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase Grant 5,480,883 - Spada , et al. January 2, 1	1996-01-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.